Form 4: Neurocrine Biosciences Executive Jude Onyia Reports Stock Transactions
SEC Form 4 Filing
Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.
Summary
- On January 31, 2025, Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences, executed transactions involving the company's common stock.
- 238 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of Neurocrine Biosciences' common stock.
- Following the vesting, 126 shares were sold at a weighted average price of $152.9681 per share, with individual sales prices ranging from $151.99 to $154.11.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 1, 2022.
- After the reported transactions, Onyia directly owns 15,561 shares of Neurocrine Biosciences common stock and 238 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an executive, with no inherent positive or negative sentiment. The transactions are part of a pre-arranged plan.
Future Outlook
The remaining 238 shares of the RSU award will vest on January 31, 2026, subject to the terms and conditions of the award.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- Rule 10b5-1 trading plans are widely used by corporate insiders to sell company stock in a pre-planned manner, mitigating the risk of insider trading allegations.
- The reported weighted average sales price of $152.9681 per share can be compared to the trading prices of Neurocrine Biosciences (NBIX) on January 31, 2025, to assess the transaction's impact.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
- The vesting of RSUs is part of the executive's compensation package, aligning their interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 2022-09-01 | Date of adoption of Rule 10b5-1 trading plan |
| 2022-01-31 | Date the RSU was granted to the Reporting Person |
| 2023-01-31 | Date the RSU award vested as to 237 shares |
| 2024-01-31 | Date the RSU award vested as to 237 shares |
| 2025-01-31 | Date of transaction: vesting of RSUs and sale of shares; RSU award vested as to 238 shares |
| 2026-01-31 | Date the RSU award will vest as to 238 shares |
| 2025-02-04 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.